

Demographic Information:

Patient Name _____ Date of Birth _____

Home Address _____

City, State, Zip _____

Home Phone _____ Mobile or Work Phone _____

Primary Insurance Name _____

Primary Insurance ID _____ Primary Insurance Group _____

Insured Name _____ Insured Date of Birth _____

Secondary Insurance Name _____ Insurance ID _____ Insurance Group _____

Secondary Insurance ID _____ Secondary Insurance Group _____

Ordering Physician's Name _____

Address _____

City, State, Zip _____

Phone _____ Fax _____

NPI _____

Please fax the following information:

History and Physical Pertinent Lab Work

Front & Back copy(s) of patient's insurance card(s)

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription, and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Physician Signature: _____
 Date: _____

Prescription: Intravenous Immunoglobulin Subcutaneous Immunoglobulin

0.4 gm/kg 1gm/kg 2gm/kg _____ grams

Infuse: IV daily x _____ day(s); repeat every _____ week(s) x _____ cycles Infuse _____ grams OR _____ mls

Other: _____ using _____ sites _____ time(s) per week

Hydration order: _____ mls NS iv to be infused prior/post IVIG. for _____ months.

Pre-medications: Acetaminophen 650mg PO 30 mins prior to infusion Other Pre-medications: _____

Diphenhydramine 25mg PO 30 mins prior to infusion

Clinical Information: Patient Weight: _____ Height: _____ Allergies: _____

IV access [for IVIg patients only]: _____ Nurse to place PIV prior to therapy

Diagnosis (Neuromuscular):	ICD-10	Diagnosis (Immune Deficiency):	ICD-10
<input type="checkbox"/> Autoimmune Encephalopathy	G04.81	<input type="checkbox"/> CVID 83.9	D83.9
<input type="checkbox"/> Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	G61.81	<input type="checkbox"/> Hypogammaglobulinemia -primary humoral immunodeficiency	D80.7
<input type="checkbox"/> Chronic Inflammatory Sensory Polyradiculopathy (CISP)	G61.81	<input type="checkbox"/> IgG sub class deficiency	D80.3
<input type="checkbox"/> Chronic Severe Myasthenia Gravis with Exacerbation & Disability	G70.01	<input type="checkbox"/> Specific Antibody deficiency	D80.6
<input type="checkbox"/> Myasthenic Crisis	G70.01	<input type="checkbox"/> Agammaglobulinemia -primary humoral immunodeficiency	D80.0
<input type="checkbox"/> Dermatomyositis <input type="checkbox"/> Polymyositis	M33.10 M33.2	<input type="checkbox"/> Chronic lymphocytic leukemia (CLL) with frequent infections and 2 IgG levels are less than 400mg/d	C91.10
<input type="checkbox"/> Guillain-Barre Syndrome (GBS)	G61.0	<input type="checkbox"/> Agranulocytosis	D70.0
<input type="checkbox"/> Hereditary sensory neuropathy	G60.0	<input type="checkbox"/> Bone marrow transplant patients (for prevention of infection or GVH prevention)	Z94.81
<input type="checkbox"/> Idiopathic Progressive Polyneuropathy	G60.3	<input type="checkbox"/> Acquired immunosuppression IgG <400 & recurrent infections	D84.81
<input type="checkbox"/> Idiopathic Thrombocytopenic Purpura	D69.3	<input type="checkbox"/> B Cell (CLL) Leukemia IgG <500 , recurrent infections	C91.1
<input type="checkbox"/> Multifocal Motor Neuropathy	G61.82	<input type="checkbox"/> CMV viremia	B25.9
<input type="checkbox"/> Multiple myeloma and immunoproliferative neoplasms	C90.0	<input type="checkbox"/> HIV infected children	C46.9
<input type="checkbox"/> Neuromyelitis Optica & MOG syndrome	G36.0	<input type="checkbox"/> Toxic Shock Syndrome (Staphylococcal or Streptococcal)	A48.3
<input type="checkbox"/> PANDAS / PANS	D89.9	<input type="checkbox"/> Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy	T45.1X5A
<input type="checkbox"/> Peroneal muscular atrophy	G60.0	<input type="checkbox"/> Varicella and Tetanus post exposure prophylaxis	B01.9
<input type="checkbox"/> Rasmussen Encephalitis	G04.90	Diagnosis (Dermatology):	
<input type="checkbox"/> Relapsing Remitting Multiple Sclerosis (RRMS)	G35.1	<input type="checkbox"/> Progressive autoimmune mucocutaneous blistering disease; this include pemphigus vulgaris, pemphigusfoliaceus, bullous pemphigoid and mucous membrane pemphigoid. Behcet's syndrome, Wegener's granulomatosis	L10.9
<input type="checkbox"/> Severe Refractory Myasthenia Gravis (MG)	G70.0		
<input type="checkbox"/> Solid organ transplant recipients at risk for cytomegalovirus infections\pneumonia	Z94.9		
<input type="checkbox"/> Stiff Person Syndrome	G25.82		
<input type="checkbox"/> Anemia with parvovirus B19	B34.3		
<input type="checkbox"/> Antiphospholipid syndrome	D68.61		

Please Draw:

CBC/diff CMP IgG w/subclasses 1-4 Quant. Ig

_____ _____ Frequency: _____

PER Anaphylaxis Protocol:

Adult – EpiPen 0.3 auto-injector dual pack

Pediatric – EpiPen 0.15 auto-injector dual pack

* Administer intramuscularly in the event of ADR*
 [May repeat x 1. Order is valid for 1 year]. **Use generic if applicable**

Notes:

If applicable, flush intravenous access device per KabaFusion protocol:		
Access	NS	Heparin
Peripheral	1-3ml before/after use	10u/ml 1-2mls after last NS flush
Midline, central (non-port), PICC	NS 5-10 mls before/after use; 10mls after blood draw	10 u/ml 3-5mls after last NS flush; 5mls after blood draw
Implanted Port	5-10mls before/after use; 20mls after blood draw	100 u/ml 5mls after last NS flush; 5mls after blood draw
Tunneled	5-10mls before/after use; 20mls after blood draw	10 u/ml 3- mls after last NS flush. 5mls after blood draw
Groshong PICC, Midline	5-10mls before/after use; 10mls after blood draw	NO Heparin needed